{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Minneapolis&page=101&state=Minnesota",
    "query": {
      "state": "Minnesota",
      "city": "Minneapolis",
      "page": 101
    },
    "page_size": 10
  },
  "pagination": {
    "page": 101,
    "page_size": 10,
    "total_count": 7884,
    "total_pages": 789,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Minneapolis&page=102&state=Minnesota&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Minneapolis&page=100&state=Minnesota&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T16:11:48.325Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03922724",
      "title": "Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral T-cell Lymphomas",
        "Lymphoproliferative Disorders",
        "Immune System Diseases"
      ],
      "interventions": [
        {
          "name": "ATL-RIC",
          "type": "DRUG"
        },
        {
          "name": "mRIC",
          "type": "DRUG"
        },
        {
          "name": "allo HCT",
          "type": "PROCEDURE"
        },
        {
          "name": "RIC",
          "type": "DRUG"
        },
        {
          "name": "GVHD prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "IOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "12 Years to 120 Years"
      },
      "enrollment_count": 118,
      "start_date": "2019-04-18",
      "completion_date": "2030-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-19",
      "last_synced_at": "2026-11-20T16:11:48.325Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03922724"
    },
    {
      "nct_id": "NCT02226796",
      "title": "Transcranial Direct Stimulation (tDCS) and Behavioral Intervention in Aphasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aphasia"
      ],
      "interventions": [
        {
          "name": "Transcranial direct current stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "20 Years to 85 Years"
      },
      "enrollment_count": 3,
      "start_date": "2015-09-01",
      "completion_date": "2018-12-01",
      "has_results": true,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-11-20T16:11:48.325Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02226796"
    },
    {
      "nct_id": "NCT00034879",
      "title": "Iressa Expanded Access Program (EAP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma",
        "Non-small-cell Lung",
        "Metastases",
        "Neoplasm"
      ],
      "interventions": [
        {
          "name": "ZD1839 (Gefitinib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-08",
      "completion_date": "2003-10",
      "has_results": false,
      "last_update_posted_date": "2013-01-04",
      "last_synced_at": "2026-11-20T16:11:48.325Z",
      "location_count": 626,
      "location_summary": "Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 623 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gadsen",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00034879"
    },
    {
      "nct_id": "NCT02122796",
      "title": "A Pilot Trial to Assess the Impact of Acupuncture on Post-mastectomy Pain, Nausea, Anxiety and Ability to Cope",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Acupuncture",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Allina Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2014-06",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2018-04-02",
      "last_synced_at": "2026-11-20T16:11:48.325Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02122796"
    },
    {
      "nct_id": "NCT02579603",
      "title": "Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "Pirfenidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2015-10-16",
      "completion_date": "2017-01-31",
      "has_results": true,
      "last_update_posted_date": "2018-02-13",
      "last_synced_at": "2026-11-20T16:11:48.325Z",
      "location_count": 6,
      "location_summary": "Danbury, Connecticut • New Orleans, Louisiana • Minneapolis, Minnesota + 3 more",
      "locations": [
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Chesterfield",
          "state": "Missouri"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02579603"
    },
    {
      "nct_id": "NCT00003191",
      "title": "Fenretinide in Treating Children With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "fenretinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 18,
      "start_date": "1998-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-07",
      "last_synced_at": "2026-11-20T16:11:48.325Z",
      "location_count": 25,
      "location_summary": "Duarte, California • Long Beach, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003191"
    },
    {
      "nct_id": "NCT02957682",
      "title": "Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Praluent (Alirocumab)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 2176,
      "start_date": "2016-11-02",
      "completion_date": "2020-03-05",
      "has_results": true,
      "last_update_posted_date": "2021-05-07",
      "last_synced_at": "2026-11-20T16:11:48.325Z",
      "location_count": 73,
      "location_summary": "Auburn, Alabama • Birmingham, Alabama • Mobile, Alabama + 63 more",
      "locations": [
        {
          "city": "Auburn",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Gatos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02957682"
    },
    {
      "nct_id": "NCT00273182",
      "title": "InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) Registry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heart Failure",
        "Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "InSync Model 8040",
          "type": "DEVICE"
        },
        {
          "name": "InSync III Model 8042",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medtronic Cardiac Rhythm and Heart Failure",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1999,
      "start_date": "2002-03",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2013-08-05",
      "last_synced_at": "2026-11-20T16:11:48.325Z",
      "location_count": 82,
      "location_summary": "Birmingham, Alabama • Peoria, Arizona • Fort Smith, Arkansas + 79 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00273182"
    },
    {
      "nct_id": "NCT00248040",
      "title": "Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ischemia-Reperfusion Injury",
        "Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Reparixin continuous infusion",
          "type": "DRUG"
        },
        {
          "name": "reparixin intermittent infusion",
          "type": "DRUG"
        },
        {
          "name": "placebo infusion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2005-10",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2024-01-10",
      "last_synced_at": "2026-11-20T16:11:48.325Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00248040"
    },
    {
      "nct_id": "NCT03099174",
      "title": "This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Xentuzumab",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2017-05-04",
      "completion_date": "2024-05-16",
      "has_results": true,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-11-20T16:11:48.325Z",
      "location_count": 6,
      "location_summary": "Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03099174"
    }
  ]
}